Tita-Nwa et al demonstrated that CD19/CD5 bsAb enhanced the cytotoxicity of CIK cells against CD19+ B cell lymphoma lines in vitro and suggested that these results supported the experimental use of the in vivo bsAb models (15). Here, CD5 is linked to B-cell non-Hodgkin lymphoma.